Advertisement

Baseline chronic kidney disease does not predict long-term renal functional decline after percutaneous nephrolithotomy

  • Kara L. WattsEmail author
  • Abhishek Srivastava
  • Wilson Lin
  • Daniel Schoenfeld
  • Matthew Abramowitz
  • Joshua M. Stern
Original Paper

Abstract

To compare renal functional outcomes in patients with and without chronic kidney disease (CKD) to identify predictors of change in renal function after percutaneous nephrolithotomy (PCNL). We reviewed patients who underwent PCNL by a single surgeon over 3.5 years. Patients’ pre- and post-operative Glomerular Filtration Rate (GFR) was calculated. Baseline GFR < 60 ml/min/1.73 m2 (stage ≥ 3 CKD) defined our CKD cohort. Patients’ baseline renal function, comorbidities, stone parameters, and intra-operative variables were analyzed to determine the relationship with post-operative renal function after PCNL by multivariate analysis. 202 patients were analyzed. Mean follow-up time was 16 months. At baseline, 163 (80.7%) patients were free of CKD and 39 (19.3%) had CKD. Patients without CKD had an overall decrease in GFR from 105.6 to 103.3 ml/min/1.73 m2 (p = 0.494). 14/163 (8.6%) non-CKD patients experienced a significant decline in renal function after PCNL; 7/163 (4.3%) developed de novo CKD and 7 had a ≥ 30% decline in GFR. Patients with CKD had an overall increase in mean GFR post-operatively, from 47.3 to 54.0 ml/min/m2 (p = 0.067). Two in this cohort (5.1%) experienced a > 30% decline in renal function post-operatively. Age, gender, African American race, presence of comorbidities and pre-operative CKD were not significant predictors of renal function post-operatively on multivariate analysis. PCNL in this cohort appears GFR neutral in the setting of baseline CKD. CKD was not predictive of renal functional decline after PCNL. Given that stone disease carries a high recurrence rate and that CKD is associated with stone formers, further investigation into predictors of renal function change after PCNL is warranted.

Keywords

PCNL CKD Renal function Kidney stone 

Notes

Funding

None.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Litwin M, Saigal C (2012) Economic impact of urologic disease, N.I.o.H. National Institute of Diabetes and Digestive and Kidney Diseases, US Department of Health and Human Services, Editor. 2012: Urologic Diseases in America. NIH Publication 12-7865, Washington, DC, p 486Google Scholar
  2. 2.
    Alexander RT et al (2012) Kidney stones and kidney function loss: a cohort study. BMJ 345:e5287CrossRefGoogle Scholar
  3. 3.
    Ferraro PM et al (2013) History of kidney stones and the risk of coronary heart disease. JAMA 310(4):408–415CrossRefGoogle Scholar
  4. 4.
    Melton LJ III et al (1998) Fracture risk among patients with urolithiasis: a population-based cohort study. Kidney Int 53(2):459–464CrossRefGoogle Scholar
  5. 5.
    Edvardsson VO et al (2013) Temporal trends in the incidence of kidney stone disease. Kidney Int 83(1):146–152CrossRefGoogle Scholar
  6. 6.
    Akman T et al (2012) The impact of metabolic syndrome on long-term outcomes of percutaneous nephrolithotomy (PCNL). BJU Int 110(11 Pt C):E1079–E1083CrossRefGoogle Scholar
  7. 7.
    Bilen CY et al (2008) Impact of percutaneous nephrolithotomy on estimated glomerular filtration rate in patients with chronic kidney disease. J Endourol 22(5):895–900CrossRefGoogle Scholar
  8. 8.
    Shoag J et al (2014) Risk of chronic and end stage kidney disease in patients with nephrolithiasis. J Urol 192(5):1440–1445CrossRefGoogle Scholar
  9. 9.
    El-Zoghby ZM et al (2012) Urolithiasis and the risk of ESRD. Clin J Am Soc Nephrol 7(9):1409–1415CrossRefGoogle Scholar
  10. 10.
    Rule AD et al (2009) Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol 4(4):804–811CrossRefGoogle Scholar
  11. 11.
    Kurien A et al (2009) The impact of percutaneous nephrolithotomy in patients with chronic kidney disease. J Endourol 23(9):1403–1407CrossRefGoogle Scholar
  12. 12.
    Preminger GA, Lingerman JE, Nakada SY, Pearle MS, Wolf JS (2009) Report on the management of staghorn calculi (2005). Clinical guidelines 2005. https://www.auanet.org/education/guidelines/staghorn-calculi.cfm. Accessed 2015
  13. 13.
    Ozden E et al (2012) Long-term outcomes of percutaneous nephrolithotomy in patients with chronic kidney disease: a single-center experience. Urology 79(5):990–994CrossRefGoogle Scholar
  14. 14.
    Kuzgunbay B et al (2010) Long-term renal function and stone recurrence after percutaneous nephrolithotomy in patients with renal insufficiency. J Endourol 24(2):305–308CrossRefGoogle Scholar
  15. 15.
    Stevens LA, Viswanathan G, Weiner DE (2010) Chronic kidney disease and end-stage renal disease in the elderly population: current prevalence, future projections, and clinical significance. Adv Chronic Kidney Dis 17(4):293–301CrossRefGoogle Scholar
  16. 16.
    Ordon M et al (2015) A population based study of the changing demographics of patients undergoing definitive treatment for kidney stone disease. J Urol 193(3):869–874CrossRefGoogle Scholar
  17. 17.
    Eknoyan G (2003) Meeting the challenges of the new K/DOQI guidelines. Am J Kidney Dis 41(5 Suppl):3–10CrossRefGoogle Scholar
  18. 18.
    Levey AS, Coresh J (2012) Chronic kidney disease. Lancet 379(9811):165–180CrossRefGoogle Scholar
  19. 19.
    Drew DA et al (2017) Association between soluble Klotho and change in kidney function: the health aging and body composition study. J Am Soc Nephrol 28(6):1859–1866CrossRefGoogle Scholar
  20. 20.
    Go AS et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351(13):1296–1305CrossRefGoogle Scholar
  21. 21.
    Sigurjonsdottir VK et al (2015) Impact of nephrolithiasis on kidney function. BMC Nephrol 16:149CrossRefGoogle Scholar
  22. 22.
    Sairam K et al (2012) Percutaneous nephrolithotomy and chronic kidney disease: results from the CROES PCNL global study. J Urol 188(4):1195–1200CrossRefGoogle Scholar
  23. 23.
    Collins AJ et al (2011) US renal data system 2010 annual data report. Am J Kidney Dis 57(1 Suppl 1):A8 (e1–526) Google Scholar
  24. 24.
    Wuerzner G et al (2010) Marked association between obesity and glomerular hyperfiltration: a cross-sectional study in an African population. Am J Kidney Dis 56(2):303–312CrossRefGoogle Scholar
  25. 25.
    Hsu CY et al (2009) Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 169(4):342–350CrossRefGoogle Scholar
  26. 26.
    Rosenberg M, Hsu CY (2004) Chronic kidney disease and progression. NephSAP 3(6):304–308Google Scholar
  27. 27.
    Derose SF et al (2013) Racial differences in estimated GFR decline, ESRD, and mortality in an integrated health system. Am J Kidney Dis 62(2):236–244CrossRefGoogle Scholar
  28. 28.
    Nouralizadeh A, Sichani MM, Kashi AH (2011) Impacts of percutaneous nephrolithotomy on the estimated glomerular filtration rate during the first few days after surgery. Urol Res 39(2):129–133CrossRefGoogle Scholar
  29. 29.
    Handa RK et al (2010) Time-course for recovery of renal function after unilateral (single-tract) percutaneous access in the pig. J Endourol 24(2):283–288CrossRefGoogle Scholar
  30. 30.
    Perez-Fentes D et al (2014) Does percutaneous nephrolithotomy and its outcomes have an impact on renal function? Quantitative analysis using SPECT-CT DMSA. Urolithiasis 42(5):461–7CrossRefGoogle Scholar
  31. 31.
    Handa RK et al (2015) Percutaneous renal access: surgical factors involved in the reduction of renal function. J Endourol 30(2):178–183CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Kara L. Watts
    • 1
    • 2
    • 4
    Email author
  • Abhishek Srivastava
    • 1
    • 4
  • Wilson Lin
    • 2
    • 5
  • Daniel Schoenfeld
    • 2
    • 6
  • Matthew Abramowitz
    • 3
  • Joshua M. Stern
    • 1
    • 2
    • 7
  1. 1.Department of UrologyMontefiore Medical CenterBronxUSA
  2. 2.Albert Einstein College of MedicineBronxUSA
  3. 3.Department of Medicine (Nephrology)Montefiore Medical CenterBronxUSA
  4. 4.BronxUSA
  5. 5.BronxUSA
  6. 6.BronxUSA
  7. 7.BronxUSA

Personalised recommendations